359 related articles for article (PubMed ID: 33922556)
1. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
De Wispelaere W; Annibali D; Tuyaerts S; Lambrechts D; Amant F
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922556
[TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy.
Lee J; Kim EH
Front Oncol; 2023; 13():1233376. PubMed ID: 37614504
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X
Front Immunol; 2022; 13():915094. PubMed ID: 36189283
[TBL] [Abstract][Full Text] [Related]
6. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy.
Gu Y; Zhang Z; Ten Dijke P
Cell Mol Immunol; 2023 Apr; 20(4):318-340. PubMed ID: 36823234
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer resistance mechanisms: challenges to immunotherapy.
Hanna A; Balko JM
Breast Cancer Res Treat; 2021 Nov; 190(1):5-17. PubMed ID: 34322780
[TBL] [Abstract][Full Text] [Related]
8. Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy.
Baumann D; Offringa R
Cell Stress; 2020 Aug; 4(10):248-251. PubMed ID: 33024933
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E; Barysauskas CM; Solomon S; Tahlil K; Malley R; Hohos M; Polson K; Loucks M; Severgnini M; Patel T; Cunningham A; Rodig SJ; Hodi FS; Morgan JA; Merriam P; Wagner AJ; Shapiro GI; George S
Cancer; 2017 Sep; 123(17):3285-3290. PubMed ID: 28440953
[TBL] [Abstract][Full Text] [Related]
10. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
11. A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance.
Huang Q; Lei Y; Li X; Guo F; Liu M
Front Cell Dev Biol; 2020; 8():580140. PubMed ID: 33344447
[TBL] [Abstract][Full Text] [Related]
12. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall GV; Hamilton A; Ratnayake G; Scott C; Barker H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326717
[TBL] [Abstract][Full Text] [Related]
13. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
14. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
[TBL] [Abstract][Full Text] [Related]
15. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.
Santiago-Sánchez GS; Fabian KP; Hodge JW
Cancer Biol Ther; 2024 Dec; 25(1):2308097. PubMed ID: 38306161
[TBL] [Abstract][Full Text] [Related]
16. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.
Sun B; Xun Z; Zhang N; Liu K; Chen X; Zhao H
Cancer Cell Int; 2023 Dec; 23(1):313. PubMed ID: 38066642
[TBL] [Abstract][Full Text] [Related]
18. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
20. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]